Evicenter
MarkdownMedical informationP&T meetings
Vonaprument (ANX007)

Geographic atrophy secondary to age-related macular degeneration

Launch
Not announced
Last updated
167 sources

Section 3 of 6

Product information and disease description

274 evidence topics · 130 sources

Product description

Phase of product development

Launch

No evidence found.

Product information

Generic, brand name and therapeutic class of product
Brand name

No evidence found.

Dosage forms and strengths
Concentration, commercial presentation, packaging, and storage

No evidence found.

Average sales price and wholesale acquisition cost

Not applicable.

American hospital formulary service (AHFS), or other drug classification
AHFS classification and ATC code for vonaprument

No evidence found.

Indication
Pharmacology
Mechanism of action
Pharmacodynamics
Pharmacokinetics
Vitreous half-life in humans

No evidence found.

Contraindications/Warnings/Precautions/Adverse effects
Warnings and precautions

Not applicable.

Special populations
Age of enrolled participants: ARCHER and ARCHER II
CharacteristicARCHER (N = 270)ARCHER II (N = 659)
Age, mean (SD)“80.0 (8.2)”“78.4 (8.0)”
Pediatric use, renal impairment, and hepatic impairment

No evidence found.

Drug/Drug, drug/disease interactions
Effects of other drugs on Vonaprument
Clinical drug interaction studies

No evidence found.

Effects of Vonaprument on other drugs
Clinical drug interaction studies

No evidence found.

Dosing and administration
Dosage
Proposed labeled dose, dosing interval, and dose modification

No evidence found.

Administration
Needle gauge, delivery device, and post-injection monitoring instructions for the commercial product

No evidence found.

Access and distribution
Expanded access program, HCPCS code, distribution channel, and REMS

No evidence found.

Co-prescribed/Concomitant therapies
ARCHER II: concomitant and prior therapy criteria

No evidence found.

Use with pegcetacoplan or avacincaptad pegol

No evidence found.

Effect of Vonaprument on quality measures
Product-specific effect on quality measures

No evidence found.

Product comparison
Head-to-head trial data against pegcetacoplan or avacincaptad pegol

No evidence found.

Place of product in therapy

Disease description

Definition and etiology
Genetic risk: heritability and the CFH and ARMS2-HTRA1 loci
Epidemiology
Incidence of Geographic atrophy secondary to age-related macular degeneration
Prevalence of Geographic atrophy secondary to age-related macular degeneration
Natural history, survival, and mortality
Pathophysiology
Disease mechanism: stressors of the RPE, drusen, and complement-mediated inflammation
Complement system: three lines of evidence in geographic atrophy
Classical pathway and C1q in geographic atrophy: sponsor-authored review

“However, the involvement of the different complement pathways (classical, lectin, alternative), and thus the optimal complement inhibition target, has yet to be fully defined. There is evidence that C1q, the initiating molecule of the classical pathway, is a key driver of complement activity in AMD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Multiple lines of evidence suggest that the classical pathway may be a key initiator of complement activation in GA. First, C1q is present in all layers of the outer retina in GA along with numerous C1q-activating ligands that accumulate throughout disease initiation and progression. Second, C1q and the classical pathway are implicated by retinal pathology in GA and in animal models of GA. Third, in RPE culture models, C1q triggers C5b-9 deposition on basement membrane components and contributes to induction of the inflammasome and cell necrosis. Fourth, inhibition of C1q and downstream C4 is protective in animal models of photoreceptor cell loss. Fifth, C1q accumulates on photoreceptor cell synapses in mice with age and light-induced injury, consistent with the unique role it plays in synapse elimination and neurodegeneration in other disorders.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“C1q is highly expressed in infiltrating macrophages within all layers of the outer retina (OPL, POS, RPE, and choroid layers) in GA” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Diagnosis
Guideline initial evaluation: history elements
Element of the initial historyQuoted text
Symptom: distortion“Metamorphopsia”
Symptom: reduced acuity“Decreased vision”
Symptom: central field loss“Scotoma”
Symptom: low-luminance function“Difficulties in dark adaptation”
Family history“Family history, especially family history of AMD”
Social history“Social history, especially a quantitative smoking history”
Fundus autofluorescence: decreased signal over atrophy and regulatory acceptance as a trial endpoint
Clinical presentation - signs and symptoms
Long-term morbidity
Burden of Geographic atrophy secondary to age-related macular degeneration
Humanistic burden and health-related quality of life
Economic burden and healthcare resource utilization
Healthcare resource utilization rate ratios: United States Medicare Advantage claims
Societal cost of illness per person with geographic atrophy: United States estimate
Direct and indirect ophthalmic resource use and costs: United Kingdom, Germany, Ireland, and Canada
Economic impact of Geographic atrophy secondary to age-related macular degeneration on families
Economic impact of diagnostic testing
Medicare national average office-based payment for retinal imaging, 2025 and 2026
CPT code2025 non-facility total RVUs2026 non-facility total RVUs2025 non-facility pay2026 non-facility payChange in non-facility pay, 2025 to 2026
92134 (OCT, retina)“0.97”“0.98”“$31.38”“$32.73”“4.32%”
92137 (OCT angiography, retina)“1.76”“1.79”“$56.93”“$59.79”“5.02%”
92250 (fundus photography)“1.1”“1.11”“$35.58”“$37.07”“4.20%”
92235 (fluorescein angiography)“4.72”“4.86”“$152.68”“$162.33”“6.32%”

Approaches to treatment

Current treatment options and standard of care
Antioxidant vitamin and mineral supplementation
AREDS formulation and progression to advanced AMD

“Participants were randomly assigned to receive daily oral tablets containing: (1) antioxidants (vitamin C, 500 mg; vitamin E, 400 IU; and beta carotene, 15 mg); (2) zinc, 80 mg, as zinc oxide and copper, 2 mg, as cupric oxide; (3) antioxidants plus zinc; or (4) placebo.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Average follow-up of the 3640 enrolled study participants, aged 55–80 years, was 6.3 years, with 2.4% lost to follow-up. Comparison with placebo demonstrated a statistically significant odds reduction for the development of advanced AMD with antioxidants plus zinc (odds ratio [OR], 0.72; 99% confidence interval [CI], 0.52–0.98).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The only statistically significant reduction in rates of at least moderate visual acuity loss occurred in persons assigned to receive antioxidants plus zinc (OR, 0.73; 99% CI, 0.54–0.99).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Those with extensive intermediate size drusen, at least 1 large druse, noncentral geographic atrophy in 1 or both eyes, or advanced AMD or vision loss due to AMD in 1 eye, and without contraindications such as smoking, should consider taking a supplement of antioxidants plus zinc such as that used in this study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Supplementation and geographic atrophy progression toward the fovea: post hoc analysis of AREDS and AREDS2

“Post hoc analysis of the Age-Related Eye Diseases Study (AREDS) and AREDS2, multi-center randomized placebo-controlled trials of oral micronutrient supplementation, each with 2×2 factorial design.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“392 eyes (318 participants) with GA in AREDS; 1210 eyes (891 participants) with GA in AREDS2.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“In AREDS eyes with non-central GA (n=208), proximity-based progression towards the central macula was significantly slower with randomization to antioxidants versus none, at 50.7 μm/year (95% CI 38.0–63.4 μm/year) versus 72.9 μm/year (95% CI 61.3–84.5 μm/year; p=0.012), respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“In AREDS2 eyes with non-central GA, in participants assigned to AREDS antioxidants without β-carotene (n=325 eyes), proximity-based progression was significantly slower with randomization to lutein/zeaxanthin versus none, at 80.1 μm/year (95% CI 60.9–99.3 μm/year) versus 114.4 μm/year (95% CI 96.2–132.7 μm/year; p=0.011), respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“In AREDS eyes with any GA (n=392), area-based progression was not significantly different with randomization to antioxidants versus none (p=0.63).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Oral micronutrient supplementation slowed GA progression towards the central macula, likely by augmenting the natural phenomenon of foveal sparing.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Photobiomodulation
Complement c3 inhibitors
OAKS and DERBY: GA lesion growth from baseline to month 24
Study and groupRate of GA lesion area growth (mm2), slope (SE)Difference (95% CI) in slope from sham pooledPercent difference from sham pooled
OAKS, pegcetacoplan monthly“3.11 (0.148)”“−0.87”“(−1.27 to −0.47)”“−21.9%”
OAKS, pegcetacoplan every other month“3.26 (0.134)”“−0.72”“(−1.10 to −0.33)”“−18.1%”
OAKS, sham pooled“3.98 (0.143)”“NA”“NA”
DERBY, pegcetacoplan monthly“3.28 (0.125)”“−0.73”“(−1.14 to −0.31)”“−18.1%”
DERBY, pegcetacoplan every other month“3.31 (0.129)”“−0.70”“(−1.11 to −0.28)”“−17.4%”
DERBY, sham pooled“4.00 (0.169)”“NA”“NA”
Complement c5 inhibitors
GATHER2: 12-month primary endpoint and safety
Vision rehabilitation
Limitations of current therapies
Summary: limitations of complement inhibitor therapy

Two intravitreal complement inhibitors are approved by the FDA for geographic atrophy: pegcetacoplan (C3 inhibitor), given every 25 to 60 days, and avacincaptad pegol (C5 inhibitor), given once monthly (approximately every 28 ± 7 days). Both reduced the growth of geographic atrophy lesions in sham-controlled phase 3 trials (pegcetacoplan by 22% monthly and 18% every other month at 24 months in OAKS; avacincaptad pegol by 14% in square-root-transformed growth at 12 months and by 14% at 24 months with monthly dosing in GATHER2). Neither improved visual function: the AAO Preferred Practice Pattern states that “There was no benefit for BCVA in the clinical trials for either pegcetacoplan or avacincaptad pegol”, and the 2023 Cochrane review of 10 randomized trials (4052 participants) found “no evidence that complement inhibition with any agent improves functional endpoints in advanced AMD”. The avacincaptad pegol finding of fewer eyes with persistent vision loss comes from a post hoc analysis of 12-month data.

Treatment requires indefinite intravitreal injections. In OAKS and DERBY, 21% to 31% of participants in the pegcetacoplan arms discontinued treatment before month 24. In a retrospective real-world cohort of eyes treated with pegcetacoplan or avacincaptad pegol, retention declined over the first 12 months, and pegcetacoplan treatment (hazard ratio 3.32), new neovascular AMD (odds ratio 3.02), and poor baseline visual acuity were associated with attrition.

Both products increase conversion to neovascular AMD: 12% with monthly and 7% with every-other-month pegcetacoplan against 3% with control by month 24, and 12% with avacincaptad pegol against 9% with sham over 24 months in GATHER2. Pegcetacoplan carries a warning for retinal vasculitis and/or retinal vascular occlusion, which may occur with the first dose and may cause severe vision loss. A postmarketing case series confirmed retinal vasculitis in 14 eyes of 13 patients, all after the first injection, with a more than 6-line loss of visual acuity in 6 eyes (43%); the guideline cites a postmarketing rate of 0.01% per injection. No retinal vasculitis was reported in the pivotal trials, which had no protocol for angiography in eyes with intraocular inflammation.

Neither product is authorized in the European Union. The European Medicines Agency confirmed its recommendation to refuse marketing authorisation for pegcetacoplan on 19 September 2024 because slowing lesion growth “did not lead to clinically meaningful benefits for patients”, and Astellas withdrew its application for avacincaptad pegol on 24 October 2024 after the Agency's provisional opinion that the product could not have been authorised. NICE suspended its appraisal of pegcetacoplan in February 2025, after the company reported that it did not receive marketing authorisation from the MHRA and has since discontinued it. The guideline notes that long-term, real-world data for both products are lacking.

Pooled effects of complement inhibitors on visual acuity, lesion growth, and adverse events

“Ten RCTs with 4052 participants and eyes with GA were included.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“For 242 participants in one study, pegcetacoplan probably did not meaningfully change BCVA given monthly (+1.05 letters, 95% CI −2.71 to 4.81) or EOM (−1.42 letters, 95% CI −5.25 to 2.41), as supported by moderate‐certainty evidence.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“These reductions correspond to 19.2% and 14.8% versus sham, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“In a study of 260 participants with extrafoveal or juxtafoveal GA, monthly avacincaptad pegol probably did not result in a clinically meaningful change in BCVA at 2 mg (+1.39 letters, 95% CI −5.89 to 8.67) or 4 mg (−0.28 letters, 95% CI −8.74 to 8.18), based on moderate‐certainty evidence.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“However, there is currently no evidence that complement inhibition with any agent improves functional endpoints in advanced AMD; further results from the phase 3 studies of pegcetacoplan and avacincaptad pegol are eagerly awaited.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Progression to MNV or exudative AMD is a possible emergent adverse event of complement inhibition, requiring careful consideration should these agents be used clinically.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Intravitreal administration of complement inhibitors is probably associated with a small risk of endophthalmitis, which may be higher than that of other intravitreal therapies.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Place in treatment, anticipated use, and care setting
Summary: anticipated use and care setting

Vonaprument is not approved for any use. In the phase 3 ARCHER II trial it is given as 5.0 mg per eye by monthly intravitreal injection, which places its anticipated use among physician-administered intravitreal therapies, the same route and setting as the two approved complement inhibitors for geographic atrophy, pegcetacoplan and avacincaptad pegol. The AAO Preferred Practice Pattern states that the ophthalmologist should administer all treatment and anti-VEGF injections for AMD. A U.S. expert panel recommends nonurgent referral to a retina specialist for any suspected geographic atrophy and notes that current anti-complement therapy requires “office visits every 1 to 2 months”.

In a footnote that begins “Based on market reports”, the sponsor estimates that approximately 75,000 U.S. patients are actively treated with available therapies, about 10% of the 800,000 people diagnosed with geographic atrophy or under the care of retina specialists and about 5% of an estimated 1.5 million U.S. people with geographic atrophy. Medicare Part B fee-for-service data for 2025 record 32,021 beneficiaries with 168,366 claims for pegcetacoplan and 27,497 beneficiaries with 140,741 claims for avacincaptad pegol, with total spending of about $451.1 million and $364.9 million. For the first quarter of 2026 the counts were 24,179 and 23,315 beneficiaries. No source states a planned price, distribution model, or position in a treatment sequence for vonaprument.

Heterogeneity of treatment effect
Care management intervention strategies
Other product development or post-marketing obligations required by the FDA

Not applicable.

Ongoing post-approval monitoring

Not applicable.

Expected outcomes of therapy